Cargando…

The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis

Rationale: Hedgehog (Hh) pathway plays an essential role in liver fibrosis by promoting the proliferation of hepatic stellate cells (HSCs) by enhancing their metabolism via yes-associated protein 1 (YAP1). Despite the presence of several inhibitors, Hh signaling cannot be controlled exclusively due...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Virender, Dong, Yuxiang, Kumar, Vinod, Almawash, Saud, Mahato, Ram I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831471/
https://www.ncbi.nlm.nih.gov/pubmed/31695785
http://dx.doi.org/10.7150/thno.38913
_version_ 1783465977409699840
author Kumar, Virender
Dong, Yuxiang
Kumar, Vinod
Almawash, Saud
Mahato, Ram I.
author_facet Kumar, Virender
Dong, Yuxiang
Kumar, Vinod
Almawash, Saud
Mahato, Ram I.
author_sort Kumar, Virender
collection PubMed
description Rationale: Hedgehog (Hh) pathway plays an essential role in liver fibrosis by promoting the proliferation of hepatic stellate cells (HSCs) by enhancing their metabolism via yes-associated protein 1 (YAP1). Despite the presence of several inhibitors, Hh signaling cannot be controlled exclusively due to their poor efficacy and the lack of a suitable delivery system to the injury site. Therefore, it is rationale to develop new potent Hh inhibitors and suitable delivery carriers. Methods: Based on the structure and activity of Hh inhibitor GDC-0449, we replaced its sulfonamide group with two methylpyridine-2yl at amide nitrogen to synthesize MDB5. We compared the Hh pathway inhibition and anti-fibrotic effect of MDB5 with GDC-0449 in vitro. Next, we developed MDB5 loaded micelles using our methoxy poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol (PEG-PCC-g-DC) copolymer and characterized for physicochemical properties. We evaluated the therapeutic efficacy of MDB5 loaded micelles in common bile duct ligation (CBDL) induced liver fibrosis, mouse model. We also determined the intrahepatic distribution of fluorescently labeled micelles after MDB5 treatment. Results: Our results show that MDB5 was more potent in inhibiting Hh pathway components and HSC proliferation in vitro. We successfully developed MDB5 loaded micelles with particle size of 40 ± 10 nm and drug loading up to 10% w/w. MDB5 loaded micelles at the dose of 10 mg/kg were well tolerated by mice, without visible sign of toxicity. The serum enzyme activities elevated by CBDL was significantly decreased by MDB5 loaded micelles compared to GDC-0449 loaded micelles. MDB5 loaded micelles further decreased collagen deposition, HSC activation, and Hh activity and its target genes in the liver. MDB5 loaded micelles also prevented liver sinusoidal endothelial capillarization (LSEC) and therefore restored perfusion between blood and liver cells. Conclusions: Our study provides evidence that MDB5 was more potent in inhibiting Hh pathway in HSC-T6 cells and showed better hepatoprotection in CBDL mice compared to GDC-0449.
format Online
Article
Text
id pubmed-6831471
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-68314712019-11-06 The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis Kumar, Virender Dong, Yuxiang Kumar, Vinod Almawash, Saud Mahato, Ram I. Theranostics Research Paper Rationale: Hedgehog (Hh) pathway plays an essential role in liver fibrosis by promoting the proliferation of hepatic stellate cells (HSCs) by enhancing their metabolism via yes-associated protein 1 (YAP1). Despite the presence of several inhibitors, Hh signaling cannot be controlled exclusively due to their poor efficacy and the lack of a suitable delivery system to the injury site. Therefore, it is rationale to develop new potent Hh inhibitors and suitable delivery carriers. Methods: Based on the structure and activity of Hh inhibitor GDC-0449, we replaced its sulfonamide group with two methylpyridine-2yl at amide nitrogen to synthesize MDB5. We compared the Hh pathway inhibition and anti-fibrotic effect of MDB5 with GDC-0449 in vitro. Next, we developed MDB5 loaded micelles using our methoxy poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol (PEG-PCC-g-DC) copolymer and characterized for physicochemical properties. We evaluated the therapeutic efficacy of MDB5 loaded micelles in common bile duct ligation (CBDL) induced liver fibrosis, mouse model. We also determined the intrahepatic distribution of fluorescently labeled micelles after MDB5 treatment. Results: Our results show that MDB5 was more potent in inhibiting Hh pathway components and HSC proliferation in vitro. We successfully developed MDB5 loaded micelles with particle size of 40 ± 10 nm and drug loading up to 10% w/w. MDB5 loaded micelles at the dose of 10 mg/kg were well tolerated by mice, without visible sign of toxicity. The serum enzyme activities elevated by CBDL was significantly decreased by MDB5 loaded micelles compared to GDC-0449 loaded micelles. MDB5 loaded micelles further decreased collagen deposition, HSC activation, and Hh activity and its target genes in the liver. MDB5 loaded micelles also prevented liver sinusoidal endothelial capillarization (LSEC) and therefore restored perfusion between blood and liver cells. Conclusions: Our study provides evidence that MDB5 was more potent in inhibiting Hh pathway in HSC-T6 cells and showed better hepatoprotection in CBDL mice compared to GDC-0449. Ivyspring International Publisher 2019-10-12 /pmc/articles/PMC6831471/ /pubmed/31695785 http://dx.doi.org/10.7150/thno.38913 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Kumar, Virender
Dong, Yuxiang
Kumar, Vinod
Almawash, Saud
Mahato, Ram I.
The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
title The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
title_full The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
title_fullStr The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
title_full_unstemmed The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
title_short The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
title_sort use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831471/
https://www.ncbi.nlm.nih.gov/pubmed/31695785
http://dx.doi.org/10.7150/thno.38913
work_keys_str_mv AT kumarvirender theuseofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT dongyuxiang theuseofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT kumarvinod theuseofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT almawashsaud theuseofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT mahatorami theuseofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT kumarvirender useofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT dongyuxiang useofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT kumarvinod useofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT almawashsaud useofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis
AT mahatorami useofmicellestodeliverpotentialhedgehogpathwayinhibitorforthetreatmentofliverfibrosis